BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• Financial Calendar for Zealand Pharma in 2018

  Zealand’s Annual General Meeting will be held on April 19, 2018.

  November 30, 2017

   · 

  1 min read
• Leti Develops Meg Technology to Improve Diagnosis of Epilepsy and Guide Surgeons During Brain Surgery

  MEG is an imaging technique that measures brain functioning based on magnetic fields produced by the brain’s electrical activity.

  November 30, 2017

   · 

  3 min read
• Policy

  EMA Accepts MAAs for Mylan and Biocon’s Proposed Biosimilars Trastuzumab and Pegfilgrastim

  EMA acceptance of the submissions follows an earlier withdrawal of both applications in response to an audit conducted by the European inspecting authority of Biocon’s drug product facility.

  November 30, 2017

   · 

  7 min read
• Tikcro Technologies Announces 2017 Annual General Meeting

  Tikcro Technologies today announced that its Annual General Meeting of Shareholders will be held on January 4, 2018 at 9:30 a.m. Israel time, at the office of the Company at 7 Sapir Street, Ness Ziona, Israel.

  November 30, 2017

   · 

  1 min read
• Business

  Probiodrug Reports Third Quarter 2017 Business Update

  The interim management report for the third quarter 2017 is available to download on the company’s website.

  November 30, 2017

   · 

  16 min read
• Drug Development

  Novartis’ Cosentyx is First Biologic to Show Long-Term Efficacy in Nail and Palmoplantar Psoriasis, Which Can Impact Up to 90% of Psoriasis Patients

  These new data from a clinical study were presented at the 8th International Congress of Psoriasis from Gene to Clinic in London, UK.

  November 30, 2017

   · 

  15 min read
• Forward Pharma Files Further Written Submissions in the European Opposition Proceeding for the EP2801355 Patent in Preparation for the Oral Hearing in January 2018

  The filing will become publicly available via the European Patent Register.

  November 30, 2017

   · 

  4 min read
• 

  Policy

  Adamis Pharmaceuticals Submits Prior Approval Supplement to FDA for the Pediatric Version of Symjepi

  Symjepi Injection 0.3mg is an FDA-approved product, for the emergency treatment of allergic reactions including anaphylaxis, designed for patients weighing 66 pounds or greater.

  November 30, 2017

   · 

  5 min read
• Drug Development

  TRACON Doses First Patient in Phase Ib Study of TRC105 With Opdivo in Patients With Lung Cancer

  The Phase 1b clinical trial is an open-label, dose-escalation and expansion cohort study of TRC105 and Opdivo in patients with non-small cell lung cancer that have received prior chemotherapy.

  November 30, 2017

   · 

  3 min read
• Business

  MorphoSys Signs Regional License Agreement for Antibody MOR202 With I-Mab

  MorphoSys to receive a USD 20 million upfront payment and entitled to tiered, double digit royalties on net sales of MOR202 plus milestone payments of up to USD 100 million from I-Mab

  November 30, 2017

   · 

  6 min read